NCT07087054 2026-03-10
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3 Recruiting
Clinical Trials
12 trialsNCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT05459844 2025-09-05
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
Phase 3 Active not recruiting
NCT03049189 2025-05-30
COMPETE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT02588170 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT02589821 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT03673943 2022-12-22
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Radiomedix, Inc.
Phase 3 Completed
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT00842348 2022-10-12
NET729
Ipsen
Phase 3 Completed
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT01524783 2021-08-05
RADIANT-4
Novartis
Phase 3 Completed